Not yet recruitingPhase 2NCT07486869
Emapalumab MDA5 Rapidly Progressive Interstitial Lung Disease (RP-ILD) Study
Studying Amyopathic dermatomyositis
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- University of Miami
- Principal Investigator
- Kelly Corbitt, D.O.University of Miami
- Intervention
- Emapalumab(drug)
- Enrollment
- 5 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2026 – 2027
Study locations (1)
- University of Miami Hospital and Clinics, Miami, Florida, United States
Collaborators
Swedish Orphan Biovitrum AB
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT07486869 on ClinicalTrials.gov